Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study-Reference-Cited by-同舟云学术

Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study

Published:2020-07-06 Issue:16 Volume:9 Page:5899-5907
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Chen Wei¹²^ORCID,Li Ziting¹,Zheng Zhong¹^ORCID,Wu Xiaohua¹^ORCID

Affiliation:

1. Department of Gynecologic Oncology Department of Oncology Fudan University Shanghai Cancer CenterShanghai Medical CollegeFudan University Shanghai China

2. Department of Obstetrics and Gynecology Minhang Hospital Fudan UniversityThe Central Hospital of Minhang District Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3282

Reference25 articles.

1. Cancer statistics, 2018

2. Epithelial ovarian cancer: Evolution of management in the era of precision medicine